Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. (20th January 2015)

• Record Type: Journal Article
• Authors: Bissonnette, R.; Maari, C.; Barber, K.; Lynde, C.W.; Vender, R.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 29:Number 8(2015:Aug.)
• Page Start: 1576
• Page End: 1581
• Publication Date: 2015-01-20
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.12943
• Languages: English
• ISSNs: 0926-9959

Abstract

<abstract abstract-type="main" id="jdv12943-abs-0001"> <title>Abstract</title> <sec id="jdv12943-sec-0001" sec-type="section"> <title>Background</title> <p>There is a paucity of data on the use of etanercept in patients who have previously failed a different tumour necrosis factor (TNF) alpha antagonist.</p> </sec> <sec id="jdv12943-sec-0002" sec-type="section"> <title>Objectives</title> <p>To study etanercept in patients who did not achieve a satisfactory response to adalimumab or who lost their response to adalimumab or infliximab and to explore the role of anti‐adalimumab and anti‐infliximab antibodies in etanercept response.</p> </sec> <sec id="jdv12943-sec-0003" sec-type="section"> <title>Methods</title> <p>Patients with psoriasis who did not achieve a satisfactory response to adalimumab or who lost their response to adalimumab or infliximab were included. All patients received etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for 12 more weeks. Anti‐infliximab and anti‐adalimumab antibodies were measured at baseline. The primary objective was to study the efficacy of etanercept using the proportion of patients who achieved a physician global assessment (PGA) of 0 or 1.</p> </sec> <sec id="jdv12943-sec-0004" sec-type="section"> <title>Results</title> <p>A total of 81 patients were included. The proportion of patients who achieved a PGA of 0 or 1 after 24 weeks of etanercept was 20.0% (95% CI 4.8–35.2%) for patients who had an unsatisfactory response to adalimumab, 35.1% (95% CI 19.0–51.3%) and 35.7% (95% CI 7.0–64.4%) for patients who lost their response to adalimumab and infliximab respectively. The proportion of patients who achieved a PGA of 0 or 1 at week 24 was numerically higher for patients who had anti‐adalimumab or anti‐infliximab antibodies (36.5%) as compared to those without (17.2%; <italic>P</italic> = 0.08).</p> </sec> <sec id="jdv12943-sec-0005" sec-type="section"> <title>Conclusions</title> <p>Etanercept can be effective in patients with psoriasis who failed a previous TNF alpha antagonist.</p> </sec> </abstract>